ACQUISITIONS - Additional Information (Details) $ in Millions |
1 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
|
Dec. 08, 2025
USD ($)
|
Jan. 03, 2025
USD ($)
therapy
|
Nov. 30, 2025
USD ($)
numberOfAcquisition
|
Mar. 31, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Dec. 09, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Asset Acquisition and Business Combination [Line Items] | |||||||
| Goodwill | $ 4,737 | $ 4,758 | $ 4,523 | ||||
| Manufacturing Equipment | |||||||
| Asset Acquisition and Business Combination [Line Items] | |||||||
| Cash consideration paid | $ 75 | ||||||
| Estimated fair value of contingent consideration | $ 35 | ||||||
| Goodwill | $ 67 | ||||||
| November 2025 Acquisitions | |||||||
| Asset Acquisition and Business Combination [Line Items] | |||||||
| Cash consideration paid | $ 33 | ||||||
| Number of acquisitions | numberOfAcquisition | 2,000,000 | ||||||
| Goodwill | $ 30 | ||||||
| Whitecap Biosciences Acquisition | |||||||
| Asset Acquisition and Business Combination [Line Items] | |||||||
| Upfront payment | $ 28 | ||||||
| Number of innovative therapies | therapy | 2 |
| X | ||||||||||
- Definition Number Of Innovative Therapies No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of businesses acquired in business combination. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|